Gyrolab Spin Blog

Sep 7, 2015 10:10:36 AM

ADC + LBA = True

The value and challenges in using ligand-binding assays to analyze Antibody-Drug Conjugates

target_v3Antibody-Drug Conjugates (ADCs) offer great potential in directing therapeutic agents directly to the target, but the complexity of their structure and dynamics in vivo present many bioanalytical challenges. In a recent review article, Seema Kumar and her colleagues at Pfizer Global R&D in the USA present a comprehensive analysis of how Ligand Binding Assays (LBAs) can be used in ADC analysis in preclinical studies.

Read More

Topics: Antibody-Drug Conjugate


Jun 5, 2014 3:05:00 PM

ADCs and bispecifics – simplifying immunoassays for complex drugs

Webinar: ’Bioanalysis of novel antibody constructs: approaches and challenges', June 10 

Immunoassay_ADC

Developing next-generation drugs demands advanced assays. A case in point is the Antibody-Drug Conjugate, which aims to deliver potent tumor-killing activity while reducing side effects for cancer patients. The ADC’s cytotoxic payload is guided to the target by the linked antibody, and determining the integrity and dynamics of such a complex molecule can require a battery of tests.You can find out more about how complex assays for ADCs and bispecifics can be simplified by joining us at the webinar.

 

Read More

Topics: Antibody-Drug Conjugate